Warm Autoimmune Hemolytic Anemia (wAIHA)
June 1, 2023
May 31, 2024
This activity is jointly provided by American Academy of CME, Inc. and and CheckRare CE.
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other members of the care team may also participate.
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new therapies under investigation which may impact treatment in the future.
This 60-minute CME program, hosted by Irina Murakhovskaya, MD, of the Montefiore Medical Center, Albert Einstein College of Medicine, in New York, NY and Bruno Fattizzo, MD, of the University of Milan and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in Milan, Italy, describes current best practices for diagnosing and managing patients with wAIHA.
After participating in the activity, learners should be better able to:
- Describe the difference between primary and secondary wAIHA
- List best practices for diagnosing wAIHA
- Describe common complications associated with wAIHA
- Explain current treatment recommendations for patients with wAIHA and the evidence which supports them
- Describe potential therapies in development for treating patients with wAIHA
Irina Murakhovskaya, MD
Montefiore Medical Center
Albert Einstein College of Medicine
New York, NY
Bruno Fattizzo, MD
University of Milan
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
- Faculty Educators
- Irina Murakhovskaya, MD discloses the following relevant relationships: Advisory Board/Consultant: Sanofi, Novartis, Alexion, Janssen, Apellis, Rigel; Grant/Research Support: Sanofi, Novartis, Alexion, Janssen, Apellis, Rigel, Incyte
- Bruno Fattizzo, MD discloses the following relevant relationships: Advisory Board/Consultant: Agios, Alexion, Annexon, Bristol Myers Squibb, Janssen, Sobi; Speaker’s Bureau: Bristol Myers Squibb, Janssen, Novartis, Sobi
Planners for this activity have no relevant financial relationships with any ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
American Academy of CME, Inc. requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. This activity will review off-label or investigational information about the following medications: prednisone, rituximab, azathioprine, cyclosporine, cyclophosphamide, mycophenolate, lemtuzumab, daratumumab, ofatumumab, tabalumab, povetacicept, obexelimab, ibrutinib, rilzabrutinib, venetoclax, fostamatinib, sovleplenib, nipocalimab, orilanolimab, annexion-005, eculizumab, pegcetacoplan, bortezomib.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
For CME questions please contact: CEServices@academycme.org